Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S329-S333. doi: 10.21037/tlcr.2018.12.02.

Authors

Chiara Lazzari¹, Vanesa Gregorc¹, Alessandra Bulotta¹, Alessia Dottore², Giuseppe Altavilla², Mariacarmela Santarpia²

Affiliations

¹ Department of Oncology, Division of Experimental Medicine, IRCCS San Raffaele Hospital, Milano, Italy.
² Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.

No abstract available

Publication types

Editorial
Comment